Source: http://www.google.com/patents/US5747510?dq=5,825,242
Timestamp: 2017-03-28 23:52:17
Document Index: 276035884

Matched Legal Cases: ['application No. 07', 'application No. 07', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08']

Patent US5747510 - Pharmaceutical unit dosage formulations - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula ##STR1## or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompased by the invention is a a pharmaceutical...http://www.google.com/patents/US5747510?utm_source=gb-gplus-sharePatent US5747510 - Pharmaceutical unit dosage formulationsAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS5747510 APublication typeGrantApplication numberUS 08/788,984Publication dateMay 5, 1998Filing dateJan 27, 1997Priority dateMar 2, 1994Fee statusPaidAlso published asCA2141999A1, CN1119530A, EP0674903A1, US5478847, US5610168, US5641790, USRE39050Publication number08788984, 788984, US 5747510 A, US 5747510A, US-A-5747510, US5747510 A, US5747510AInventorsMichael W. DraperOriginal AssigneeEli Lilly And CompanyExport CitationBiBTeX, EndNote, RefManPatent Citations (9), Non-Patent Citations (55), Referenced by (30), Classifications (20), Legal Events (3) External Links: USPTO, USPTO Assignment, EspacenetPharmaceutical unit dosage formulations
US 5747510 AAbstract
6-hydroxy-2-(4-hydroxyphenyl)-3- 4-(2-piperidinoethoxy)benzoyl!benzo b!thiophene
6-hydroxy-2-(4-hydroxyphenyl)-3 -4-(2-piperidinoethoxy)benzoyl!benzo b!thiophene
6-hydroxy-2-(4-hydroxyphenyl)-3 4-(2-piperidinoethoxy)benzoyl!benzo b!thiophene, hydrochloride
TABLE I__________________________________________________________________________Baseline Values and Mean (±SEM) Group Changes from Baseline toEndpoint in Markers of Bone Metabolism (GGGC)        Raloxifene                Raloxifene                        RaloxifenePlacebo 10 mg   50 mg   200 mgMarker(n = 42)        (n = 42)                (n = 42)                        (n = 41)__________________________________________________________________________Serum alkaline phosphatase (U/L)Baseline77.31 (±3.53)        78.71 (±3.12)                73.86 (±2.69)                        79.07 (±2.77)Change-1.10 (±2.08)        0.21 (±1.56)                -4.78 (±1.52)                        -5.93* (±1.48)Serum osteocalcin (ng/mL)Baseline3.94 (±0.21)        3.86 (±0.19)                3.65 (±0.21)                        4.21 (±0.21)Change-0.63 (±0.16)        -0.27 (±0.13)                -0.81 (±0.15)                        -1.21* (±0.18)__________________________________________________________________________ Abbreviatons: n = greatest number of subjects tested for any one marker; SEM = standard error of the mean. *Statistically significantly (p &lt; 0.051 different from placebo (twotailed comparison).
TABLE II__________________________________________________________________________Baseline Values and Mean (±SEM) Group Changes from Baseline toEndpoint in Serum Lipids (GGGC)        Raloxifene                Raloxifene                        RaloxifenePlacebo 10 mg   50 mg   200 mgVariable(n = 42)        (n = 42)                (n = 42)                        (n = 41)__________________________________________________________________________LDL-C (mmol/L)Baseline3.67 (±0.11)        4.11# (±0.17)                3.55 (±0.16)                        3.68 (±0.13)Change0.02 (±0.08)        0.05 (±0.10)                -0.23* (±0.06)                        -0.17 (±0.07)HDL-C (mmol/L)Baseline1.41 (±0.06)        1.41 (±0.06)                1.35 (±0.05)                        1.32 (±0.05)Change-0.03 (±0.03)        0.01 (±0.02)                0.04 (±0.02)                        0.02 (±0.02)HDL-C: LDL-C ratioBaseline0.40 (±0.02)        0.37 (±0.03)                0.42 (±0.03)                        0.38 (±0.02)Change-0.01 (±0.01)        0.00 (±0.01)                0.03* (±0.01)                        0.03* (±0.01)Toal cholesterol (mmol/L)Baseline5.69 (±0.12)        6.18# (±0.19)                5.82 (±0.21)                        5.71 (±0.14)Change0.10 (±0.09)        0.01 (±0.10)                -0.23* (±0.08)                        -0.15 (±0.08)__________________________________________________________________________ Abbreviations: LDLC = lowdensity lipoprotein cholesterol; HDLC = highdensity lipoprotein cholesterol; n = greatest number of subjects tested for any one marker; SEM = standard error of the mean. #Statistically significantly (p &lt; 0.050) larger than all other treatments (twotailed comparison). *Statistically significantly (p &lt; 0.050) different from placebo (twotaile comparison).
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4133814 *Sep 17, 1976Jan 9, 1979Eli Lilly And Company2-Phenyl-3-aroylbenzothiophenes useful as antifertility agentsUS4380635 *Dec 16, 1981Apr 19, 1983Eli Lilly And CompanySynthesis of acylated benzothiophenesUS4418068 *Dec 16, 1981Nov 29, 1983Eli Lilly And CompanyAntiestrogenic and antiandrugenic benzothiophenesUS5075321 *Feb 24, 1988Dec 24, 1991University Of PennsylvaniaMethods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenesUS5393763 *Jan 12, 1994Feb 28, 1995Eli Lilly And CompanyMethods for inhibiting bone lossUS5464845 *Nov 30, 1993Nov 7, 1995Eli Lilly And CompanyMethods for lowering serum cholesterolUS5641790 *Apr 14, 1995Jun 24, 1997Eli Lilly And CompanyMethods of use for inhibiting bone loss and lowering serum cholesterolWO1993010113A1 *Nov 11, 1992May 27, 1993Teikoku Hormone Mfg. Co., Ltd.Novel benzothiophene derivativeWO1993011074A1 *Nov 4, 1992Jun 10, 1993Healthguard, IncorporatedMultistage coaxial encapsulated filter assembly* Cited by examinerNon-Patent CitationsReference1Black et al., "Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors," Molecular and Cellular Endocrinology, 22:1981, 95-103.2Black et al., "Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;" The Endocrine Society, Abstract 1982.3Black et al., "Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms," Endocrinology 109;1981, 987-989.4Black et al., "Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice," Life Sciences, 26:1980, 1453-1458.5 *Black et al., Antagonism of Estrogen Action with a New benzothiophene Derived Antiestrogen, Life Sciences, 32:1983. 1031 1036.6Black et al., Antagonism of Estrogen Action with a New benzothiophene Derived Antiestrogen, Life Sciences, 32:1983. 1031-1036.7 *Black et al., Antiestrogens 2. Structure Activity Studies in a Series of 3 Aroyl 2 arylbenzo b thiophene Derivatives Leading to 6 Hydroxy 2(4 hydroxyphenyl)benzo b thien 3 yl 4 2 (1 piperidinyl)ethoxy phenyl methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med. Chem. 27(8), 1984, 1057 1066.8Black et al., Antiestrogens 2. Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo b!thiophene Derivatives Leading to 6-Hydroxy-2(4-hydroxyphenyl)benzo b!thien-3-yl! 4- 2-(1-piperidinyl)ethoxy!-phenyl!methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med. Chem. 27(8), 1984, 1057-1066.9 *Black et al., Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors, Molecular and Cellular Endocrinology, 22:1981, 95 103.10 *Black et al., Distinct, Structure Related Profiles of Estrogenic and Anti Estrogenic Activity in the Tamoxifen and LY117018 Series; The Endocrine Society, Abstract 1982.11 *Black et al., Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms, Endocrinology 109;1981, 987 989.12 *Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5 6, 1982.13Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.14Black et al., Synthesis and Antiestrogenic Activity of 3,4-Dihydro-2(4-methoxyphenyl)-1-napthalenyl! 4- 2-pyrrolidinyl) ethoxyl!-phenyl! methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22;1979, 962-966.15 *Black et al., Synthesis and Antiestrogenic Activity of 3,4 Dihydro 2(4 methoxyphenyl) 1 napthalenyl 4 2 pyrrolidinyl) ethoxyl phenyl methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22;1979, 962 966.16 *Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H LY139481 Distribution In Vivo. Sixty fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8 10, 1983, abs. 93.17Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8-10, 1983, abs. 93.18 *Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1 7, 1984, abs. 323.19Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.20 *Black et al., Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice, Life Sciences, 26:1980, 1453 1458.21Black, L.J. "Biological Actions and Binding Properites of a New Estrogen Antagosist LY117018," In: Homone Antagonists, 129-82, 1982 (M.K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.22 *Black, L.J. Biological Actions and Binding Properites of a New Estrogen Antagosist LY117018, In: Homone Antagonists, 129 82, 1982 (M.K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.23Bryant et al., "Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.24Bryant et al., "Raloxifene is a Tissue Specific Estrogen Agonist", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.25 *Bryant et al., Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats , Am Soc. Bone & Min. Res., Tampa, Sep. 18 22, 1993.26 *Bryant et al., Raloxifene is a Tissue Specific Estrogen Agonist , Am Soc. Bone & Min. Res., Tampa, Sep. 18 22, 1993.27Cypriani, B. et al., "Effect of Estradiol and Antiestrogens on Cholesterol Biosynthesis in Hormone-Dependent and Independent Breast Cancer Cell Lines," Biochimica et Biophysica Act, 972(1988) 167-178.28 *Cypriani, B. et al., Effect of Estradiol and Antiestrogens on Cholesterol Biosynthesis in Hormone Dependent and Independent Breast Cancer Cell Lines, Biochimica et Biophysica Act, 972(1988) 167 178.29Cypriani, B., et al., "Role of Estrogen Receptors and Antiestrogen Binding Sites in an Early Effect of Antiestrogens, the Inhibition of Cholesterol Biosynthesis," J. Steroid Biochem 31(5) pp. 763-771, 1988.30 *Cypriani, B., et al., Role of Estrogen Receptors and Antiestrogen Binding Sites in an Early Effect of Antiestrogens, the Inhibition of Cholesterol Biosynthesis, J. Steroid Biochem 31(5) pp. 763 771, 1988.31Draper et al., "Effects of Raloxifene (LY139481 HC1) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women", Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993.32 *Draper et al., Effects of Raloxifene (LY139481 HC1) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women , Hong Kong, Fourth Int l Symp. on Osteoporosis, Mar. 29, 1993.33Frolick et al., "In Vivo and In Vitro Metabolism of Raloxifene", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.34 *Frolick et al., In Vivo and In Vitro Metabolism of Raloxifene , Am. Soc. Bone & Min. Res., Tampa, Sep. 18 22, 1993.35Glasebrook et al., "Multiple Binding Sites for the Anti-estrogen Raloxifene", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.36 *Glasebrook et al., Multiple Binding Sites for the Anti estrogen Raloxifene , Am Soc. Bone & Min. Res., Tampa, Sep. 18 22, 1993.37Hock et al., "Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.38 *Hock et al., Combination of Raloxifene and Human Parathyoid Hormone 1 34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats , Am. Soc. Bone & Min. Res., Tampa, Sep. 18 22, 1993.39Sato et al., "DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats", Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.40 *Sato et al., DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats , Am. Soc. for Bone and Min. Res., Tampa, Sep. 18 22, 1993.41 *U.S. application No. 07/920,933, Black et al., filed Jul. 28, 1992.42 *U.S. application No. 07/995,222, Black et al., filed Dec. 22, 1992.43 *U.S. application No. 08/035,121, Black et al., filed Mar. 19, 1993.44 *U.S. application No. 08/081,610, Yang, filed Jun. 21, 1993.45 *U.S. application No. 08/082,218, Cullinan et al., filed Jun. 24, 1993.46 *U.S. application No. 08/096,480, Hock, filed Jul. 22, 1993.47 *U.S. application No. 08/111,796, Dodge et al., filed Aug. 25, 1993.48 *U.S. application No. 08/112,012, Dodge et al., filed Aug. 15, 1993.49 *U.S. application No. 08/138,642, Black et al., filed Oct. 15, 1993.50 *U.S. application No. 08/138,643, Black et al., filed Oct. 15, 1993.51 *U.S. application No. 08/170,945, Jones et al., filed Dec. 21, 1993.52 *U.S. application No. 08/422,417, Draper, filed Apr. 15, 1995.53 *U.S. application No. 08/479,585, Gibson et al., filed Jun. 7, 1995.54Yang et al., "Raloxifene an Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TGFB-3 Expression in Bone;".Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.55 *Yang et al., Raloxifene an Anti Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TGFB 3 Expression in Bone; .Am Soc. for Bone and Min. Res., Tampa, Sep. 18 22, 1993.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS6087378 *Sep 1, 1999Jul 11, 2000Eli Lilly And CompanyPharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndromeUS6096781 *Nov 4, 1998Aug 1, 2000Eli Lilly And Company2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndromeUS6251920May 21, 1998Jun 26, 2001Neorx CorporationPrevention and treatment of cardiovascular pathologiesUS6258826Sep 1, 1999Jul 10, 2001Eli Lilly And CompanyPharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndromeUS6262079May 6, 1999Jul 17, 2001Neorx CorporationPrevention and treatment of cardiovascular pathologiesUS6395769May 12, 2000May 28, 2002Eli Lilly And Company2-arylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndromeUS6491938Jun 29, 2001Dec 10, 2002Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cellsUS6569441Nov 27, 2001May 27, 2003Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cellsUS6630453May 4, 2000Oct 7, 2003Strakan LimitedAndrogen derivatives and uses thereofUS6906086May 27, 2003Jun 14, 2005Eli Lilly And CompanyMethods for inhibiting bone lossUS7504394Apr 7, 2005Mar 17, 2009WyethBazedoxifene ascorbateUS7759386Nov 20, 2007Jul 20, 2010Wyeth LlcPharmaceutical compositions of estrogenic agentsUS8067022Jul 20, 2001Nov 29, 2011Boston Scientific Scimed, Inc.Therapeutic inhibitor of vascular smooth muscle cellsUS8097642Feb 27, 2007Jan 17, 2012Boston Scientific Scimed, Inc.Therapeutic inhibitor of vascular smooth muscle cellsUS8158670Jan 4, 2007Apr 17, 2012Boston Scientific Scimed, Inc.Therapeutic inhibitor of vascular smooth muscle cellsUS20040087572 *Oct 12, 2001May 6, 2004Anderson Pamela WangMethod for inhibiting cataractsUS20040177700 *Aug 27, 2003Sep 16, 2004Rigaku CorporationStress measurement method using X-ray diffractionUS20050227964 *Apr 7, 2005Oct 13, 2005WyethBazedoxifene ascorbateUS20050227966 *Apr 7, 2005Oct 13, 2005WyethBazedoxifene acetate formulationsUS20060106010 *Jun 13, 2005May 18, 2006Black Larry JMethods for inhibiting bone lossUS20080269198 *Nov 20, 2007Oct 30, 2008WyethPharmaceutical compositions of estrogenic agentsUS20090137559 *Feb 2, 2009May 28, 2009WyethBazedoxifene ascorbateUSRE38968Feb 27, 2003Feb 7, 2006Eli Lilly And CompanyMethods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochlorideUSRE39049Feb 27, 2003Mar 28, 2006Eli Lilly And CompanyMethods for inhibiting bone lossUSRE39050Feb 27, 2003Mar 28, 2006Eli Lilly And CompanyMethods of use for inhibiting bone loss and lowering serum cholesterolEP2266590A2Feb 24, 2003Dec 29, 2010Shire LLCActive agent delivery sytems and methods for protecting and administering active agentsEP2316468A1Feb 24, 2003May 4, 2011Shire LLCDelivery system and methods for protecting and administering dextroamphetamineEP2316469A1Feb 24, 2003May 4, 2011Shire LLCDelivery system and methods for protecting and administering dextroamphetamineWO2002003987A2Jun 29, 2001Jan 17, 2002WyethPharmaceutical compositions of estrogenic agentsWO2002034266A1 *Oct 12, 2001May 2, 2002Eli Lilly And CompanyMethod for inhibiting cataracts* Cited by examinerClassifications U.S. Classification514/333, 549/51, 546/202International ClassificationA61K31/4453, A61P19/08, A61K9/107, A61K9/20, A61K31/38, A61K9/48, A61P43/00, A61P3/06, A61K31/445, A61K31/381, A61P19/10, C07D333/56, A61K31/4535Cooperative ClassificationA61K31/4535, A61K31/445European ClassificationA61K31/445, A61K31/4535Legal EventsDateCodeEventDescriptionSep 28, 2001FPAYFee paymentYear of fee payment: 4Sep 27, 2005FPAYFee paymentYear of fee payment: 8Sep 28, 2009FPAYFee paymentYear of fee payment: 12RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services